BCL6 rearrangement
|
Diffuse Large B Cell Lymphoma
|
BCL6 rearrangement
|
Diffuse Large B Cell Lymphoma
|
lisocabtagene maraleucel Sensitive: C2 – Inclusion Criteria
|
lisocabtagene maraleucel Sensitive: C2 – Inclusion Criteria
|
BCL6 rearrangement
|
Lymphoma
|
BCL6 rearrangement
|
Lymphoma
|
CAR-T immunotherapy Resistant: C3 – Early Trials
|
CAR-T immunotherapy Resistant: C3 – Early Trials
|
BCL6 rearrangement
|
Mediastinal B Cell Lymphoma
|
BCL6 rearrangement
|
Mediastinal B Cell Lymphoma
|
rituximab Sensitive: C3 – Early Trials
|
rituximab Sensitive: C3 – Early Trials
|
BCL6 rearrangement
|
Diffuse Large B Cell Lymphoma
|
BCL6 rearrangement
|
Diffuse Large B Cell Lymphoma
|
MATRix Sensitive: C4 – Case Studies
|
MATRix Sensitive: C4 – Case Studies
|
BCL6 rearrangement
|
Diffuse Large B Cell Lymphoma
|
BCL6 rearrangement
|
Diffuse Large B Cell Lymphoma
|
R-CHOP Sensitive: C4 – Case Studies
|
R-CHOP Sensitive: C4 – Case Studies
|